logo-loader
viewTesla Inc

Tesla clips price of Model Y sport utility vehicle, stock ascent continues

Model Ys began rolling out in March and by April Tesla told investors that the car was profitable

Tesla Inc - Tesla clips price of Model Y sport utility vehicle, stock ascent continues

Tesla Inc (NASDAQ:TSLA) has dropped the price of its Model Y sport utility vehicle just four months following its launch as the coronavirus (COVID-19) pandemic continues to drag on sector-wide auto sales.

Model Y pricing now starts at US$49,990, down 6% from US$52,990. Previously, in May, the price of the Model 3, Model X and Model S vehicles were also reduced.

READ: Tesla becomes the world's most valuable car company

Elon Musk’s car company earlier in July reported a decline in car deliveries, albeit the drop was better than feared by the market and suggested a more robust performance among Telsa’s new breed of electric cars compared to petroleum driven rivals.

The carmaker revealed that it had delivered nearly 90,650 vehicles in the quarter. It beat Wall Street expectations of around 74,100.

Model Ys began rolling out in March and, by April, Tesla told investors that the car was profitable.

Tesla’s shares on Friday performed strongly, rising around 10%, which in turn helped Elon Musk mark notable headlines as it meant his wealth surpassed exalted value investor Warren Buffet and he become the seventh richest person in the world (according to Bloomberg’s Billionaires Index).

Just over a week previously, Telsa was ranked as the world's most valuable car company as its second-quarter results bolstered its Nasdaq listed stock.

At that time, the California-based company had a market capitalisation of US$208bn – and, after Friday’s close, this was marked at US$286bn.

Quick facts: Tesla Inc

Price: 1501.96 USD

NASDAQ:TSLA
Market: NASDAQ
Market Cap: $279.38 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Amryt Pharma releases Q-2 financials that show strong revenue growth as...

Amryt Pharma (Nasdaq: AMYT) CEO Dr Joe Wiley joined Steve Darling from Proactive with news the company saw a nice increase in revenue as they released their Q-2 numbers. Dr Wiley talked about some of the numbers and what was driving that revenue. Wiley also told Proactive the company has, for...

48 minutes ago

2 min read